Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain
CompletedPhase 4NCT00317655
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The main purpose of this study is to investigate the ability of some dietary supplement products to affect general joint health and life quality in a selected population with back pain. The study is randomized and double - blind, with parallel groups receiving treatment for a duration of 12 weeks.
Study details
- Official title
- Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain - a Randomized, Double Blind, Placebo-Controlled Clinical Investigation With Parallel Groups for 3 Months to Enlighten Joint Health
- Conditions
- Interventions
- Drug: Glucosamine sulphate
- Drug: Ginger
- Drug: Ginger-Avocado-Soya
- Drug: Ginger-ibuprofen
- Sponsor
- Ferrosan AS
- Start date
- 2006-04
- Sex
- All
- Age range
- from 30 Years to 85 Years
- Results posted
- No results posted in this snapshot
- Countries
- Denmark
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic back pain daily or almost daily for at least 3 months prior to inclusion * Patient classified as I or II according to Quebec Task Force * No intake of glucosamine sulphate, ginger, or avocado-soya extract during last 3 months * Fertile women should, at start, have a negative pregnancy test and during test use acceptable prevention methods (p-pills, intrauterine device \[IUD\], depot gestagen, subdermal implant, hormonal vaginal ring or transdermal depot plaster). * Anxiolytics, muscle relaxants, physiotherapy, chiropractic treatment, or training should not have been used during last 3 months. Exclusion Criteria: * Serious disease (eg. heart disease, cancer (within past 5 years), kidney disease, blood diseases, inflammatory diseases (eg. chronic rheumatoid arthritis, fibromyalgia) * Suspicion that back pain is caused by osteoporosis, other arthritic condition than osteoarthritis, cancer, infection, pain from organ disease or psychosomatic cancer disease. * Uncontrolled elevated blood pressure, defined as systolic ≥ 160 mm Hg or diastolic ≥ 90 mm Hg. * VAS measurement at inclusion less than ved 30 mm or over 90 mm. * Prehistory of ulcer, stomach surgery, or inflammatory bowel disease * Pain relief medication besides must not be taken during study. * Patients in need of non-steroidal anti-inflammatory drugs (NSAIDs), morphine, or similar medication are not eligible. Same is also valid for patients in need of injections or acupuncture. * Back surgery within 6 months before inclusion or earlier surgery without effect * "Heart" aspirin (low dose), ulcer medication, or blood thinning medication * Alcohol abuse * Depression * Pregnancy or breastfeeding * Allergy to crustaceans or known intolerance for glucosamine sulphate, ginger, avocado, soy, or ibuprofen * Allergy or asthma released by salicylic acid or other arthritis medication (NSAIDs) * Patient who is seeking pension due to back pain or has other economical interests connected to his/her back pain
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00317655